Prescriber Scope of Practice for ADHD in Illinois

If you’re a psychiatrist or psychiatric nurse practitioner considering telehealth for ADHD care, you’ve probably asked yourself: Can I legally prescribe Adderall or other stimulants through a video visit? The short answer in 2026 is yes — but with important caveats that vary by state and provider type.

The regulatory landscape around prescribing controlled substances via telehealth has been in constant flux since COVID-19. Federal rules extended temporary flexibilities through December 31, 2026, while states like New York, Florida, and Texas each have their own wrinkles. For nurse practitioners, the rules get even more complex depending on whether you’re in a full practice authority state or one that requires physician collaboration.

This guide cuts through the confusion. We’ll walk through the current federal DEA rules, break down what’s allowed (and what’s not) in six key states, and explain how scope of practice differences affect psychiatrists versus PMHNPs. Whether you’re already practicing telehealth or exploring platforms like Klarity Health to expand your practice, you need to know these rules inside and out.

Federal Rules: The DEA Telehealth Extension Through 2026

Here’s what matters right now at the federal level:

The Ryan Haight Act normally requires an in-person exam before any provider can prescribe a Schedule II controlled substance (like Adderall, Vyvanse, or Ritalin). Pre-pandemic, that meant no purely virtual ADHD treatment unless you fit into a narrow exception that basically never applied.

COVID changed everything. In March 2020, the DEA waived the in-person requirement under public health emergency authority. That waiver has been extended multiple times and currently runs through December 31, 2026. This means you can prescribe ADHD medications after a telehealth evaluation — no initial in-person visit required — as long as you:

• Conduct a legitimate medical evaluation via live audio-video (not just a phone call or questionnaire)
• Issue the prescription for a legitimate medical purpose
• Follow all other controlled substance protocols (DEA registration, state PDMP checks, electronic prescribing)
• Are licensed in the patient’s state

What’s Coming: Permanent DEA Rules

The DEA announced in January 2025 that it’s finalizing three new telemedicine rules to replace the temporary waiver. Key elements that will affect ADHD prescribing:

Telemedicine Special Registration: Providers will be able to apply for a special DEA registration that authorizes prescribing controlled substances via telehealth without an in-person exam. This will require mandatory PDMP checks and patient identity verification, but it creates a permanent pathway for virtual ADHD care.

Established Patient Exception: If you’ve seen a patient in person at least once (or they were seen by someone in your practice), the new telemedicine rules won’t apply — you can continue prescribing via telehealth as you would in person.

Platform Registration: Telehealth companies will also need DEA registration, adding corporate-level oversight.

These permanent rules should take effect in 2027. Until then, the current extension gives you a clear runway to practice virtual ADHD care legally — but you should prepare for the special registration requirement ahead.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The Economic Reality: Why Platforms Beat DIY Marketing

Let’s address the elephant in the room: patient acquisition cost.

You’ll see marketing ‘experts’ claim you can acquire psychiatric patients for $30-50 through SEO or Facebook ads. That’s fantasy. Here’s the real math:

DIY Marketing True Costs:

• Google Ads for ‘ADHD treatment near me’ or ‘ADHD psychiatrist’: $15-40+ per click
• Conversion rate from click to booked appointment: typically 2-5%
• Real cost per booked patient: $200-400+ (and that’s before accounting for no-shows)
• SEO investment: 6-12 months and $3,000-5,000+ before meaningful patient flow
• Psychology Today listing: $30-80/month subscription plus you’re competing with hundreds of other providers on the same page
• Agency/consultant fees if you outsource: $2,000-5,000/month
• Your time managing campaigns, vetting leads, handling intake: 10-15 hours/week

For most providers, especially those starting out or scaling up, spending $3,000-5,000 monthly on marketing with uncertain ROI is a gamble you can’t afford.

The Platform Model:Klarity Health uses a pay-per-appointment model (similar to Zocdoc). You pay a standard listing fee per new patient lead. No upfront marketing spend. No monthly subscriptions. No wasted ad dollars on clicks that don’t convert.

The value proposition is simple:

• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients
• Guaranteed ROI: You know exactly what you’re paying per patient

Instead of gambling $5,000/month on marketing channels you may not understand, you pay only when a qualified ADHD patient books with you. That’s the economic difference between risk and certainty.

State-by-State Breakdown: Where You Can Practice

Federal law sets the floor, but states add their own requirements. Here’s what you need to know for the six highest-volume markets:

California

The Good News: California has no state-level in-person exam requirement. A telehealth evaluation meets prescribing standards, and there’s no special ban on controlled substance prescribing via telemedicine.

For Psychiatrists: Full prescribing authority. Just ensure you check the CURES database (California’s PDMP) before the initial prescription and every four months for ongoing stimulant therapy — this is mandatory.

For PMHNPs: California is transitioning to full practice authority. Experienced NPs (those who’ve completed a transition period under physician supervision) can prescribe stimulants independently as of 2023-2026. New graduate NPs need a supervising physician initially, but by 2026 the pathway to independence is clear.

Licensing: You need a full California license. California is not part of the Interstate Medical Licensure Compact and doesn’t offer a special telehealth registration for out-of-state providers.

Texas

The Challenge: Texas is one of the most restrictive states for nurse practitioners.

For Psychiatrists: You can prescribe ADHD medications via telehealth without restriction (beyond federal requirements). Texas law prohibits telemedicine for chronic pain management with controlled substances, but ADHD doesn’t fall under that exclusion.

For PMHNPs: Here’s the hard stop — nurse practitioners and PAs cannot prescribe Schedule II controlled substances in outpatient settings in Texas. Period. The only exceptions are for hospitalized patients (>24 hours), hospice, or emergency room orders.

This means if you’re an NP treating ADHD patients in Texas via telehealth, a physician must write the actual prescription. You can evaluate, diagnose, and manage care, but the MD/DO signs the script.

Practical Implication: Platforms operating in Texas either use psychiatrists for ADHD care or have collaborative physician arrangements for NPs. If you’re an NP considering Texas, factor this into your practice model.

Licensing: Texas is part of the IMLC for physicians, making it easier to get a license if you’re already practicing in another compact state.

Florida

The Pleasant Surprise: Florida explicitly permits prescribing Schedule II stimulants via telehealth for ‘treatment of a psychiatric disorder’ — which includes ADHD.

For Psychiatrists: Full authority. You can prescribe after a telehealth exam without an in-person visit. Check Florida’s E-FORCSE PDMP before prescribing (required for patients 16+).

For PMHNPs: Florida allows psychiatric NPs to prescribe stimulants without the 7-day supply restriction that applies to other APRNs prescribing Schedule II drugs. However, you must work under a protocol agreement with a supervising psychiatrist. Florida did not include psychiatric NPs in its 2020 independent practice law, so physician collaboration is required.

The Out-of-State Option: Florida created an out-of-state telehealth provider registration system. If you’re licensed in another state, you can register with Florida’s Department of Health to provide telehealth services (including prescribing ADHD meds under the psychiatric exception) without getting a full Florida license. This is a major advantage for providers wanting to expand into Florida’s market.

Licensing: Either obtain a full Florida license or use the out-of-state telehealth registration (requires clean disciplinary record, malpractice insurance, and registration with Florida’s PDMP).

New York

Recent Update: In May 2025, New York updated its regulations to explicitly align with federal telehealth rules, removing any state-level barrier to prescribing controlled substances via telemedicine.

For Psychiatrists: Full prescribing authority. You must check the I-STOP PMP registry for every Schedule II prescription (highly enforced) and use electronic prescribing (mandatory since 2016).

For PMHNPs: New York is relatively progressive. NPs with more than 3,600 hours of practice can practice independently without a written collaborative agreement, including prescribing stimulants. They still need a defined collaborative relationship with a physician (not direct supervision), but no physician co-signature is required.

Practical Tip: New York allows up to a 90-day supply of stimulants for ADHD if you note condition code ‘B’ on the prescription. This reduces refill frequency for stable patients — a real efficiency gain in telehealth practice.

Licensing: You need a full New York license. New York is not part of the IMLC for physicians, so out-of-state MDs need to go through the standard licensing process.

Pennsylvania

The Middle Ground: Pennsylvania doesn’t have state-specific telehealth prescribing restrictions beyond federal law, but NP scope is limited.

For Psychiatrists: Full authority. Follow standard controlled substance protocols and check the PA PDMP before initial prescriptions (required for any controlled substance at the start of treatment).

For PMHNPs: Pennsylvania requires collaborative agreements with physicians. CRNPs can prescribe Schedule II substances for up to a 30-day supply. Any continuation beyond 30 days requires physician consultation/approval.

This doesn’t mean the patient sees the physician — it means you need to loop in your collaborating doctor before month two. In practice, many telehealth platforms have psychiatrists review NP cases at the 30-day mark.

Licensing: Pennsylvania is part of the IMLC for physicians (joined in 2022), making it easier to obtain a license if you’re already practicing in another compact state.

Illinois

The Two-Tier System: Illinois has one of the most interesting NP regulatory structures.

For Psychiatrists: Full prescribing authority with no special state restrictions on telehealth. You need both an Illinois medical license and an Illinois Controlled Substance License (separate from your DEA registration).

For PMHNPs: Illinois offers two pathways:

Option 1 – Collaborative Practice: Under a physician collaborative agreement, you can prescribe Schedule II stimulants for up to 30 days. The collaborating physician must approve any continuation, and review your Schedule II prescribing monthly.

Option 2 – Full Practice Authority (FPA): After 4,000 hours of practice and 250 hours of continuing education, you can apply for Full Practice Authority status. With FPA, you can prescribe stimulants independently without physician collaboration or monthly reviews. The consultation requirement for Schedule II ‘narcotic drugs’ doesn’t apply to stimulants (which are non-narcotic Schedule II substances).

Practical Implication: Illinois NPs have a clear path to independence, making it an attractive market for experienced PMHNPs. If you’re FPA-certified, you can run a solo telehealth ADHD practice without physician oversight.

Licensing: You need an Illinois license plus an Illinois Controlled Substance License for any controlled substance prescribing.

Quick Reference: State Telehealth Rules for ADHD Prescribing

Standard of Care Requirements: What ‘Telehealth Evaluation’ Actually Means

Having the legal right to prescribe via telehealth doesn’t mean you can skip due diligence. Every state expects you to meet the same standard of care as in-person practice. Here’s what that means practically:

Initial Evaluation Must Include:

• Live audio-video interaction (not just a phone call or online questionnaire)
• Comprehensive psychiatric history
• Assessment using DSM-5-TR criteria for ADHD
• Review of previous diagnoses and treatments
• Screen for substance use disorders and diversion risk
• Mental status examination
• Discussion of risks, benefits, and alternatives to stimulant medication

Ongoing Requirements:

• Regular follow-up visits (frequency based on clinical judgment and state requirements)
• PDMP checks at appropriate intervals (state-specific)
• Documentation that meets your state’s medical record standards
• Informed consent for telehealth (document patient understanding)
• Emergency care plan (what the patient should do if urgent issues arise)

Red Flags That Draw Scrutiny:

• Prescribing after only asynchronous (questionnaire-based) encounters
• No documentation of diagnostic criteria
• Skipping PDMP checks
• Prescribing without discussing non-medication alternatives
• Not screening for comorbid substance use or psychiatric conditions
• Inadequate follow-up intervals

The DEA investigated several telehealth companies in 2022-2023 for alleged over-prescribing of Adderall. The lesson: follow your clinical judgment, document thoroughly, and don’t cut corners because it’s telehealth.

Compliance Checklist: What You Need to Prescribe ADHD Meds via Telehealth

Before you see your first virtual ADHD patient, make sure you have:

Licensing & Registration:

• [ ] Medical license or APRN license in the patient’s state
• [ ] DEA registration covering that state
• [ ] State-specific controlled substance license (IL, NY, others)
• [ ] PDMP account registration in that state
• [ ] Malpractice insurance covering telehealth
• [ ] If NP: collaborative agreement in place (if required by state)

Technology & Compliance:

• [ ] HIPAA-compliant telehealth platform
• [ ] Electronic prescribing system certified for controlled substances (EPCS)
• [ ] Secure documentation system (EHR)
• [ ] Process for verifying patient identity during virtual visits
• [ ] Process for verifying patient location (to confirm you’re licensed there)

Clinical Protocols:

• [ ] ADHD evaluation template meeting DSM-5-TR criteria
• [ ] PDMP check protocol (when, how often, documentation)
• [ ] Informed consent process for telehealth
• [ ] Emergency care instructions for patients
• [ ] Follow-up visit scheduling protocols

If You’re an NP in a Collaborative State:

• [ ] Physician collaborator identified and agreement executed
• [ ] Process for physician review at 30-day mark (PA, IL)
• [ ] Monthly chart review system for Schedule II prescribing (IL)
• [ ] Clear escalation protocol for complex cases

Why Platforms Like Klarity Make Sense for ADHD Care

Let’s be direct: you became a psychiatrist or PMHNP to treat patients, not to become a marketing expert, compliance specialist, and IT manager.

What You Get with a Platform Approach:

Pre-Qualified Patient Flow: Patients come to you already screened, matched to your specialty, and ready to book. No spending hours qualifying leads who aren’t appropriate for your practice.

Built-In Compliance Infrastructure: HIPAA-compliant video, integrated EHR, e-prescribing systems, PDMP access — all set up and maintained for you. No figuring out which tech stack to use or managing vendor relationships.

Multi-State Licensing Support: Guidance on which states make sense for your practice, help navigating licensing requirements, and a patient population that makes the investment worthwhile.

Payment Processing: Both insurance billing and cash-pay handled, with transparent fee structures. No chasing down payments or dealing with claim denials yourself.

Credentialing Assistance: Insurance panel credentialing is time-consuming. Platforms often handle this or provide support, getting you in-network faster.

No Marketing Spend: This is the big one. Instead of $3,000-5,000/month in marketing with uncertain results, you pay a standard fee per booked patient. That’s it. Your economics are predictable and scalable.

Clinical Freedom: You control your schedule, choose your patient population, and make all clinical decisions. The platform handles everything else.

For NPs in Restrictive States: Some platforms provide the physician collaboration infrastructure you need to practice legally (like in PA or IL for non-FPA NPs). Instead of finding and contracting with a collaborating psychiatrist yourself, it’s built into the platform model.

The alternative — building a solo telehealth practice from scratch — means you’re managing licensing in multiple states, figuring out which e-prescribing system integrates with which EHR, handling your own marketing, doing your own credentialing, and hoping you can get enough patient volume to make it sustainable. For most providers, that’s 6-12 months of setup before you see meaningful income.

What Happens After 2026? Preparing for Permanent DEA Rules

The current federal extension expires December 31, 2026. Here’s what you should be thinking about now:

Expect a Telemedicine Special Registration Requirement: The DEA’s proposed permanent rules include a special registration for providers who want to prescribe controlled substances via telehealth to new patients without an in-person exam. This will likely involve:

• An application process and fee
• Mandatory participation in a national PDMP data system
• Enhanced patient identity verification requirements
• Possibly additional training or attestations

Start Building Documentation Habits Now: The permanent rules will almost certainly include stricter documentation requirements. Practice thorough note-taking now:

• Document how you verified patient identity
• Note PDMP check results explicitly
• Record your clinical reasoning for prescribing stimulants
• Include discussion of risks and alternatives

Stay Current on Your State’s Response: States may add their own requirements once permanent federal rules are in place. Join your state psychiatric association or NP organization to get updates on proposed legislation.

If You’re an NP, Consider FPA Status: For PMHNPs in states with pathways to full practice authority (CA, IL, others), start working toward that now. The more autonomy you have, the easier it will be to adapt to regulatory changes.

Budget for Compliance Costs: Whether it’s the DEA special registration fee, additional PDMP system fees, or continuing education requirements, factor compliance costs into your practice economics.

The good news: all signals point to the DEA maintaining some form of telehealth prescribing for ADHD. The public health need is too great, and the comment period showed overwhelming support from patients and providers. The permanent rules will add safeguards, but virtual ADHD care isn’t going away.

The Bottom Line: Telehealth ADHD Prescribing in 2026

Here’s what you need to remember:

You can legally prescribe ADHD medications via telehealth right now — through December 31, 2026 — as long as you’re licensed in the patient’s state, conduct a proper evaluation via audio-video, and follow all controlled substance protocols.

State rules matter enormously, especially for nurse practitioners. Texas NPs can’t prescribe stimulants in outpatient settings at all. Pennsylvania and Illinois NPs face 30-day limits without physician involvement. California and New York NPs have much more autonomy.

The economics favor platforms over DIY. Building a solo telehealth ADHD practice means months of setup, thousands in monthly marketing spend, and uncertain patient volume. A pay-per-appointment platform gives you predictable costs, pre-qualified patients, and built-in infrastructure.

Permanent rules are coming in 2027, but they’ll likely preserve telehealth access with additional safeguards (special registration, enhanced PDMP checks). Start preparing now.

Documentation is your protection. Meet the same standard of care as in-person, document thoroughly, check PDMPs religiously, and don’t cut corners. The DEA is watching this space closely.

If you’re a psychiatrist or PMHNP interested in ADHD telehealth — whether you’re adding virtual visits to your existing practice or building a full-time telehealth practice — the opportunity is real and growing. Patient demand is high, reimbursement is improving, and the regulatory path is clearer than it’s been since 2020.

Ready to start seeing ADHD patients via telehealth without the marketing headaches? Klarity Health provides the patient flow, compliance infrastructure, and practice support you need to focus on what you do best: treating patients. Join our provider network and start building your telehealth ADHD practice with zero upfront marketing spend. Apply to join Klarity’s provider network.

Frequently Asked Questions

Can I prescribe Adderall after a video visit, or do I need to see the patient in person first?

As of February 2026, yes — you can prescribe Adderall and other Schedule II stimulants after a telehealth video evaluation without an in-person exam, thanks to the federal DEA extension through December 31, 2026. This assumes you’re licensed in the patient’s state, conduct a legitimate evaluation via live audio-video, and follow all state-specific requirements (PDMP checks, e-prescribing, etc.). After 2026, the DEA’s permanent rules will likely allow this with a special telemedicine registration.

What’s the difference between what psychiatrists and nurse practitioners can prescribe for ADHD via telehealth?

Psychiatrists (MD/DO) have full prescribing authority in all 50 states for ADHD medications via telehealth, subject only to federal and state controlled substance rules. Psychiatric nurse practitioners’ authority varies dramatically by state:

• Independent states (CA by 2026, NY after 3,600 hours, IL with FPA): PMHNPs can prescribe stimulants independently
• Collaborative states (PA, IL without FPA, FL): PMHNPs need physician oversight, with 30-day limits on Schedule II in some states
• Restricted states (TX): NPs cannot prescribe Schedule II stimulants in outpatient settings at all

Always verify your specific state’s scope of practice rules before prescribing.

Do I need to check the prescription drug monitoring program (PDMP) every time I prescribe ADHD medication?

Requirements vary by state, but best practice is yes. Many states explicitly require PDMP checks:

• New York: Check I-STOP registry for every Schedule II prescription (mandatory)
• California: Check CURES before initial prescription and every 4 months for ongoing therapy
• Florida: Check E-FORCSE before prescribing controlled substances to patients 16+
• Pennsylvania: Required before initial controlled substance prescriptions and periodically thereafter

Even in states where it’s not explicitly mandated for stimulants, checking the PDMP is the standard of care to screen for ‘doctor shopping’ and potential diversion.

Can I prescribe ADHD medication to patients in states where I’m not licensed?

No. You must hold an active license (or approved telehealth registration) in the state where the patient is physically located during the telehealth visit. Prescribing across state lines without proper licensure violates both state medical practice acts and federal controlled substance laws. Some states like Florida offer out-of-state telehealth registration options that don’t require a full license, but you must have some form of legal authority to practice in that state.

What happens if the DEA doesn’t finalize permanent rules before the December 2026 deadline?

Based on the pattern since 2023, the DEA would likely issue another extension rather than allow telehealth prescribing to lapse entirely. Congress has also shown interest in codifying telehealth flexibilities. However, providers should monitor DEA announcements closely in late 2026. If you’re building a telehealth practice, have contingency plans for what you’d do if in-person exams became required (though all signals suggest the DEA will maintain some form of telehealth access with safeguards).

Can I prescribe a 90-day supply of ADHD medication via telehealth, or am I limited to 30 days?

This depends on state law and your provider type:

• New York: Allows up to 90 days for ADHD stimulants if you note condition code ‘B’ on the prescription
• Pennsylvania NPs: Limited to 30-day prescriptions for Schedule II (physician consultation required for continuation)
• Illinois NPs (non-FPA): Same 30-day limit with physician approval needed beyond that
• Most states for MDs/DOs and independent NPs: No specific quantity limits beyond what’s clinically appropriate (though 30-90 days is typical for stimulants)

Check your state’s Board of Medicine or Pharmacy regulations for specifics. Longer supplies reduce patient hassle but require confidence in diagnosis and close monitoring.

What documentation do I need to maintain for telehealth ADHD prescribing?

You should document the same elements as an in-person visit, plus telehealth-specific items:

• Patient identity verification method
• Patient’s physical location during the visit (confirming you’re licensed there)
• Informed consent for telehealth treatment
• Comprehensive evaluation supporting ADHD diagnosis (DSM-5-TR criteria)
• PDMP check results and date
• Clinical rationale for prescribing stimulant medication
• Discussion of risks, benefits, and alternatives
• Follow-up plan and emergency care instructions
• For NPs in collaborative states: documentation of physician collaboration or review

Keep records for your state’s required retention period (typically 6-10 years). Good documentation is your best protection if your prescribing is ever questioned.

Is there any difference in reimbursement between in-person and telehealth ADHD visits?

As of 2026, most commercial insurers and Medicare/Medicaid offer parity — meaning telehealth visits are reimbursed at the same rate as in-person for mental health services. However, some plans still have telehealth-specific codes or slight variations. Key points:

• Use appropriate telehealth modifiers (GT or 95) when billing
• Check if the plan requires specific place-of-service codes
• Some state Medicaid programs have additional telehealth billing requirements
• Cash-pay rates for telehealth are typically similar to or slightly lower than in-person

Most modern telehealth platforms (including Klarity) handle billing and coding, so you don’t need to navigate the nuances yourself if you’re working through a platform.

Sources and References

The following sources were consulted to ensure accuracy and provide citations for regulatory details in this guide. All information reflects laws and guidance current as of February 2026.

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026
   Published: January 2, 2026
   https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html
   Official announcement extending controlled substance prescribing flexibilities through December 31, 2026.

2. Healthcare Dive – ‘DEA, HHS extend telehealth controlled substance prescribing flexibilities for fourth time’
   Published: January 5, 2026
   https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/
   Industry analysis of the 2026 DEA extension and its implications for Schedule II-V prescribing.

3. DEA Press Release – Three New Telemedicine Rules
   Published: January 16, 2025
   https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access
   Official DEA announcement of proposed permanent telemedicine regulations, including special registration requirements and PDMP mandates.

4. RxAgent Blog – NP Prescriptive Authority by State (2026 Guide)
   Updated: December 28, 2025
   https://rxagent.co/blog/np-prescribing-authority
   Comprehensive state-by-state guide to nurse practitioner scope of practice and prescribing authority.

5. Texas Board of Nursing – APRN Practice FAQ
   Current as of 2025
   https://www.bon.texas.gov/faqpracticeaprn.asp.html
   Official guidance on Texas APRN prescribing limitations, including Schedule II restrictions.

6. Florida Statutes §456.47 – Telehealth Provisions
   Effective: July 2019 (current through 2025)
   https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html
   Florida law establishing telehealth practice standards and psychiatric disorder exception for Schedule II prescribing.

7. Florida Statutes §464.012 – Nursing Prescriptive Authority
   Updated: 2016-2017
   https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&StatuteYear=2017&URL=0400-0499/0464/Sections/0464.012.html
   Florida statute detailing APRN prescribing rules, including 7-day limitation and psychiatric nurse exception.

8. New York State Department of Health – Bureau of Narcotic Enforcement Guidance on Telehealth Controlled Substance Prescribing
   Effective: May 21, 2025
   https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth
   Official New York guidance aligning state regulations with federal telehealth rules and detailing PDMP requirements.

9. Pennsylvania Code Title 49 – Chapter 21 (CRNP Prescriptive Authority)
   Last amended: December 2009 (current through 2025)
   https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html
   Pennsylvania administrative code establishing 30-day supply limits for CRNP Schedule II prescribing.

10. Illinois Administrative Code – Nurse Practice Act Rules (68 IL Adm. Code 1300)
    Current through 2024
    https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300
    Illinois regulations governing APRN collaborative agreements, Full Practice Authority criteria, and Schedule II prescribing requirements.

11. Center for Connected Health Policy – State Telehealth Laws: Online Prescribing
    Updated: January 2026
    https://www.cchpca.org/topic/online-prescribing/
    Policy repository aggregating state-specific telehealth and online prescribing laws.

All regulatory claims in this article were verified against official government sources (state statutes, regulations, medical board publications, and DEA/HHS releases) to ensure accuracy as of February 10, 2026.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care